United States Glioblastoma Treatment Market 2033 | Growth Drivers, Key Players & Investment Opportunities | Emerging Players - IN8bio Inc., Sapience Therapeutics, Inc.,GT Medical Technologies, Inc., VBI Vaccines Inc.

Market Size and Growth

The Global Glioblastoma Treatment market size reached US$ 2.74 billion in 2024 and is expected to reach US$ 5.77 billion by 2033, growing at a CAGR of 8.7% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glioblastoma-treatment-market?sb

Key Development:

United States: Recent Glioblastoma Developments

✅ In December 2025, Imvax announced that IGV-001 delivered a median overall survival of 20.3 months in a randomized Phase 2b trial for newly diagnosed glioblastoma (ndGBM), marking a 6.3‐month improvement over placebo.

✅ In November 2025, Tinostamustine received orphan‐drug designation from the U.S. Food and Drug Administration (FDA) for malignant gliomas paving the way for continued clinical development in glioblastoma.

✅ Also in November 2025, early Phase 1 results for Tinostamustine in unmethylated‐MGMT glioblastoma (uMGMT GBM) showed tolerable safety at doses of 80-100 mg/m2 and preliminary signs of clinical activity, supporting its inclusion in the global adaptive trial GBM AGILE.

✅ In November 2025, Temferon investigated in the TEM‐GBM Phase 1/2a study for newly diagnosed glioblastoma (uMGMT) reported 18‐month survival at 44% among treated patients, with a median overall survival of 17 months.

✅ In November 2025, a preclinical study introduced a novel peptide‐design framework (POTFlow) using generative modeling to create therapeutic peptides targeting ATP5A, showing significant inhibition of glioblastoma tumor viability in patient‐derived xenograft (PDX) models a promising new direction for peptide‐based GBM therapies.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glioblastoma-treatment-market

Japan: Recent Glioblastoma‐Relevant Developments

✅ In August 2025, SymBio Pharmaceuticals announced that preclinical data on Brincidofovir for malignant brain tumors including glioblastoma was accepted for presentation at the upcoming Society for Neuro-Oncology Annual Meeting (SNO), highlighting potential future interest in GBM.

Europe: Recent Glioblastoma Developments

✅ In September 2025, Prevision Medicine launched a new "Glioblastoma Drug‐Screening Test" a precision‐medicine platform designed to help oncologists rapidly identify the most effective therapies for individual GBM patients based on tumor‐cell sensitivity.

✅ In September 2025, a Europe‐wide immunotherapy‐based retrospective and prospective study by GLIOMATCH received ethical approval to analyze data from adult and paediatric glioma/GBM patients from multiple neuro‐oncology centers an important milestone for collaborative, multi‐center research aiming to improve personalized GBM care.

Key Players:

=> Merck & Co., Inc., Pfizer Inc., Amneal Pharmaceuticals LLC, USWM, LLC., Amgen Inc., Day One Biopharmaceuticals, Inc., Servier Pharmaceuticals LLC, and among others.

Emerging market players

=> Laminar Pharma, Sapience Therapeutics, Inc., IN8bio Inc., GT Medical Technologies, Inc., Nanopharmaceutics, Inc., Chimeric Therapeutics Ltd., VBI Vaccines Inc., and Others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glioblastoma-treatment-market?sb

Key Segments:

By Treatment Type

Chemotherapy leads with 45% share, driven by widespread adoption for various cancer types, established protocols, and availability across hospitals and clinics globally. Immunotherapy accounts for 30%, supported by growing adoption of targeted therapies, checkpoint inhibitors, and personalized cancer treatments. Electric-field therapy holds 10%, reflecting emerging adoption in specific solid tumor treatments and research-stage applications. Other treatment types make up 15%, including photodynamic therapy, gene therapy, and combination therapies addressing niche oncology indications.

By Type of Molecule

Small molecules dominate with 55% share, fueled by oral and parenteral formulations, cost-effectiveness, and established manufacturing and regulatory frameworks. Biologics account for 45%, driven by the rising adoption of monoclonal antibodies, cell-based therapies, and targeted protein therapeutics in oncology.

By Route of Administration

Oral administration leads with 50% share, driven by convenience, patient compliance, and widespread availability in outpatient settings. Parenteral administration accounts for 50%, supported by intravenous and subcutaneous delivery of chemotherapy agents, biologics, and combination therapies requiring clinical supervision.

By End-User

Hospitals dominate with 65% share, fueled by inpatient oncology care, specialized cancer treatment centers, and infrastructure for advanced therapies. Clinics account for 25%, reflecting outpatient treatments, targeted therapy administration, and follow-up care. Other end-users make up 10%, including research centers, homecare providers, and specialized oncology units.

By Region

North America - 40% Share
North America leads with 40%, driven by advanced healthcare infrastructure, high cancer prevalence, and early adoption of novel therapies in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by established oncology centers, government healthcare programs, and research-driven adoption in Germany, France, U.K., Italy, Spain, and neighboring regions.

Asia Pacific - 20% Share
Asia Pacific accounts for 20%, fueled by growing cancer incidence, increasing healthcare expenditure, and rising accessibility to advanced treatments in China, Japan, India, and Southeast Asia.

Latin America - 7% Share
Latin America holds 7%, driven by expanding oncology care, hospital networks, and adoption of cost-effective treatment protocols in Brazil, Mexico, and surrounding countries.

Middle East & Africa - 8% Share
The Middle East & Africa represent 8%, supported by increasing investments in healthcare infrastructure, rising cancer awareness, and availability of chemotherapy and immunotherapy in GCC countries, South Africa, and other emerging markets.

FAQ

What is the current size of the Glioblastoma Treatment Market?

A: In 2024, the Glioblastoma Treatment Market was valued at US$ 2.74 billion, reflecting its strong industry presence.

Q2: How large is the Glioblastoma Treatment Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Glioblastoma Treatment Market will grow to around US$ 5.77 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Glioblastoma Treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 8.7% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.